Manufacturer GENWAY
Type Antibody
Specific against Human
Applications IP
Amount 0.02 mg
Host Mouse
ArtNr 20-783-314902
Genway ID:
IgG1Species Cross Reactivity: Reacts with: Rhesus MonkeyN. B. Antibody reactivity and working conditions may vary between species.
Purified IgG prepared by affinity chromatography on Protein A.
Buffer Solution:
Phosphate buffered saline
Preservative Stabilisers:
0. 09% Sodium AzideApprox. Protein Concentrations: IgG concentration 1. 0 mg/ml
Recognises the isoform of the leucocyte common antigen encoded by exon B and stains B cells most T cells and monocytes. Clone MEM55 immunoprecipitates bands of 190 200 and 205kD. Recommended Negative Controls: MOUSE IgG1 NEGATIVE CONTROLRecommended Secondary Antibodies: Rabbit Anti Mouse IgGGoat Anti Mouse IgGGoat Anti Mouse IgG (H/L)Goat Anti Mouse IgG IgA IgMHuCAL Anti Mouse IgG1Goat Anti Mouse IgG (Fc)Sheep Anti Mouse IgG (H/L)
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation recruits and dephosphorylates SKAP1 and FYN. Ref. 6Ref. 8Catalytic activityProtein tyrosine phosphate + H2O = protein tyrosine + phosphate. Subunit structureBinds GANAB and PRKCSH By similarity. Interacts with SKAP1. Interacts with DPP4; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Ref. 8Ref. 9Subcellular locationMembrane; Single-pass type I membrane protein. Membrane raft.
Colocalized with DPP4 in membrane rafts. Ref. 9
The first PTPase domain interacts with SKAP1. Post-translational modificationHeavily N- and O-glycosylated. Ref. 13Ref. 14Involvement in diseaseDefects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T-B+NK+ SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID) a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity leukopenia and low or absent antibody levels. Patients present in infancy recurrent persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Ref. 18Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. Ref. 17Sequence similaritiesBelongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily. Contains 2 fibronectin type-III domains. Contains 2 tyrosine-protein phosphatase domains.
Amount: 0.02 mg
Available: In stock
Listprice: €152.38
Discount: -10.0%
Price: €137.14
You save: €15.24

Get an offer

Technische Fragen zu diesem Produkt?

Salesmanager: Arne Pelz